GCP
MRNA icon

GSA Capital Partners’s Moderna MRNA Stock Holding History

GSA Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$297K Sell
4,235
-25,003
-86% -$1.29M 0.02% 1307
2026
Q1 		$1.49M Buy
29,238
+3,664
+14% +$171K 0.09% 288
2025
Q4 		$754K Sell
25,574
-13,348
-34% -$363K 0.07% 540
2025
Q3 		$1M Buy
38,922
+26,617
+216% +$742K 0.08% 392
2025
Q2 		$339K Buy
+12,305
New +$324K 0.02% 1183
2025
Q1 		– Sell
-5,944
Closed -$247K – 1925
2024
Q4 		$247K Buy
5,944
+302
+5% +$14.4K 0.02% 1316
2024
Q3 		$377K Buy
+5,642
New +$518K 0.03% 1108
2024
Q1 		– Sell
-2,703
Closed -$269K – 1840
2023
Q4 		$269K Buy
+2,703
New +$227K 0.02% 1172
2022
Q4 		– Sell
-2,149
Closed -$254K – 1731
2022
Q3 		$254K Buy
+2,149
New +$326K 0.03% 1041
2022
Q2 		– Sell
-1,868
Closed -$322K – 1658
2022
Q1 		$322K Buy
+1,868
New +$314K 0.04% 843
2021
Q2 		– Sell
-3,078
Closed -$403K – 1502
2021
Q1 		$403K Sell
3,078
-1,609
-34% -$233K 0.07% 468
2020
Q4 		$490K Buy
+4,687
New +$474K 0.08% 436
2019
Q3 		– Sell
-18,062
Closed -$264K – 1591
2019
Q2 		$264K Buy
+18,062
New +$388K 0.03% 1084

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

GSA Capital Partners's MRNA Position: Q2 2026 in Review

GSA Capital Partners reduced its Moderna (MRNA) stake by 86% in Q2 2026, selling an estimated $1.29M and leaving 4,235 shares worth $297K. The position accounts for 0.02% of the portfolio, ranked #1307.

GSA Capital Partners first reported a position in MRNA in Q2 2019 and has held it in 13 quarters since. The position peaked at $1.49M in Q1 2026. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • GSA Capital Partners held 4,235 shares of Moderna worth $297K as of Q2 2026.
  • GSA Capital Partners sold 25,003 Moderna shares in Q2 2026, an estimated $1.29M.
  • Moderna made up 0.02% of GSA Capital Partners's portfolio in Q2 2026, its #1307 holding.
  • GSA Capital Partners first reported a position in Moderna in Q2 2019 and has held it in 13 quarters since.
  • GSA Capital Partners's Moderna position peaked at $1.49M in Q1 2026.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.